Genentec announced the launch of Evrysdi (risdiplam) for Spinal Muscular Atrophy Market
Growing initiatives to enhance the treatment option for rare diseases is propelling the growth of the S pinal M uscular A trophy M arket . For instance, in 2017, the U.S. FDA granted an orphan drug license to RG7916, a joint development program by Roche, SMA Foundation, and PTC Therapeutics for the treatment of SMA. Similarly, the Orphan Drug Designation was also granted to Cytokinetics’ CK-2127107 by U.S. FDA in May 2017. Moreover, increasing initiatives by people and non-profit organizations for creating awareness regarding SMA is another key factor augmenting the growth of the market. For instance, in January 2018, the National Institute for Health and Care Excellence (NICE) invited Biogen to submit a single technology appraisal for Spinraza to enable NHS funding. NICE and NHS, U.K. are developing a managed access agreement for a long-term reimbursement plan for Biogen’s Spinraza. In January 2019, Biogen announced that the first spinal muscular atrophy (S...